PIPE-307 Dose A + PIPE-307 Dose B + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing Remitting Multiple Sclerosis
Conditions
Relapsing Remitting Multiple Sclerosis
Trial Timeline
Nov 6, 2023 → Aug 4, 2025
NCT ID
NCT06083753About PIPE-307 Dose A + PIPE-307 Dose B + Placebo
PIPE-307 Dose A + PIPE-307 Dose B + Placebo is a phase 2 stage product being developed by Contineum Therapeutics for Relapsing Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06083753. Target conditions include Relapsing Remitting Multiple Sclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06083753 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsing Remitting Multiple Sclerosis